My records go back to the first dose with dates, so I can reconstruct the timeline exactly.
I would like to know the limits of what can be inferred from this.
What I am trying to avoid is over-reading a single result, which I have done before.
What would I need in addition before this supported a decision?
More usefully, escalating while symptomatic resets the tolerance process and is the mechanism behind most miserable titrations.
The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.
The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.
The top of the schedule is not the target. The working dose is.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsAnswer first: the titration schedule exists to let tolerance to the gastrointestinal effects develop between steps, and every step in it is a tolerability decision rather than an efficacy one.
Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
More usefully, the dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Four half-lives between steps, minimum. Work it out for your agent.
The part that matters: this is the single most consequential controllable variable in the whole experience, and people routinely rush it.
Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.
Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.
Hold rather than escalate while symptoms are active. Always.
The short version: four-weekly steps for the weekly agents, hold rather than escalate when symptoms are active, and slower is always available.
For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.
A schedule described here is a published schedule for a licensed product and is not a recommendation.
Stepping back is a normal adjustment, not a failure.
edited 7 Nov 2025 by Dr_Colm_Fitzhenry — removed a claim I could not source
Answering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.
Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.
The caveat is that titration decisions belong with a clinician who knows what else is on board.
Slower costs time and nothing else. The ceiling is the same.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.